<!DOCTYPE html>
<html lang="en">

<head>
  <!-- Charset + Viewport -->
  <meta charset="utf-8" />
  <meta name="viewport" content="width=device-width, initial-scale=1, viewport-fit=cover" />

  <!-- Indexing & Privacy -->
  <meta name="robots" content="noindex, nofollow" />
  <meta name="referrer" content="strict-origin-when-cross-origin" />

  <!-- Theming & UX -->
  <meta name="color-scheme" content="light dark" />
  <meta name="theme-color" content="#003366" />
  <meta name="format-detection" content="telephone=no, address=no, email=no" />
  <meta name="apple-mobile-web-app-capable" content="yes" />
  <meta name="apple-mobile-web-app-status-bar-style" content="default" />
  <meta name="mobile-web-app-capable" content="yes" />

  <!-- Title + Description -->
  <title>Consideration of Nabiximols (Sativex®) Trial for Central Neuropathic Pain — James Saint</title>
  <meta name="description" content="Formal request to consider a monitored trial of Nabiximols (Sativex) for central neuropathic pain." />

  <!-- Canonical -->
  

  <!-- Open Graph -->
  <meta property="og:title" content="Consideration of Nabiximols (Sativex®) Trial for Central Neuropathic Pain — James Saint" />
  <meta property="og:description" content="Formal request to consider a monitored trial of Nabiximols (Sativex) for central neuropathic pain." />
  <meta property="og:type" content="article" />
  <meta property="og:url" content="" />
  <meta property="og:site_name" content="James Saint" />
  <meta property="og:locale" content="en_GB" />
  <meta property="og:image" content="https://jamessaint.github.io/images/seed-of-life-gold-default.png" />
  <meta property="og:image:width" content="1200" />
  <meta property="og:image:height" content="630" />

  <!-- Twitter Cards -->
  <meta name="twitter:card" content="summary_large_image" />
  <meta name="twitter:title" content="Consideration of Nabiximols (Sativex®) Trial for Central Neuropathic Pain — James Saint" />
  <meta name="twitter:description" content="Formal request to consider a monitored trial of Nabiximols (Sativex) for central neuropathic pain." />
  <meta name="twitter:image" content="https://jamessaint.github.io/images/seed-of-life-gold-default.png" />

  <!-- App Icons + Manifest -->
  <link rel="apple-touch-icon" sizes="180x180" href="https://jamessaint.github.io/images/icons/apple-touch-icon.png" />
  <link rel="icon" type="image/png" sizes="32x32" href="https://jamessaint.github.io/images/icons/favicon-32x32.png" />
  <link rel="icon" type="image/png" sizes="16x16" href="https://jamessaint.github.io/images/icons/favicon-16x16.png" />
  <link rel="manifest" href="https://jamessaint.github.io/site.webmanifest" />
  <link rel="mask-icon" href="https://jamessaint.github.io/images/icons/safari-pinned-tab.svg" color="#003366" />
  <meta name="msapplication-TileColor" content="#003366" />

  <!-- Preconnect/DNS Prefetch for performance -->
  <link rel="preconnect" href="https://cdn.jsdelivr.net" crossorigin>
  <link rel="preconnect" href="https://fonts.googleapis.com">
  <link rel="preconnect" href="https://fonts.gstatic.com" crossorigin>
  <link rel="dns-prefetch" href="//cdn.jsdelivr.net">
  <link rel="dns-prefetch" href="//fonts.googleapis.com">
  <link rel="dns-prefetch" href="//fonts.gstatic.com">

  <!-- CSS Framework + Fonts -->
  <link href="https://cdn.jsdelivr.net/npm/bootstrap@5.3.3/dist/css/bootstrap.min.css" rel="stylesheet" />
  <link href="https://fonts.googleapis.com/css2?family=Montserrat:wght@300;400;600;700&display=swap" rel="stylesheet">
  <link href="https://jamessaint.github.io/medical/global_styles.css" rel="stylesheet" />

  <!-- Mild Content Security Policy -->
  <meta http-equiv="Content-Security-Policy" content="
    default-src 'self';
    img-src 'self' https: data:;
    style-src 'self' 'unsafe-inline' https://fonts.googleapis.com https://cdn.jsdelivr.net;
    font-src 'self' https://fonts.gstatic.com data:;
    connect-src 'self';
    frame-ancestors 'none';
    base-uri 'self';
    form-action 'self'
  ">

  <!-- Structured Data -->
  <script type="application/ld+json">
  {
    "@context": "https://schema.org",
    "@type": "WebPage",
    "name": "Consideration of Nabiximols (Sativex®) Trial for Central Neuropathic Pain — James Saint",
    "url": "",
    "description": "Formal request to consider a monitored trial of Nabiximols (Sativex) for central neuropathic pain.",
    "inLanguage": "en-GB",
    "isPartOf": { "@type": "WebSite", "name": "James Saint", "url": "https://jamessaint.github.io/" }
  }
  </script>
</head>

<body>
    <main class="content container">
          <nav aria-label="breadcrumb">
            <ol class="breadcrumb">
                <li class="breadcrumb-item"><a href="/medical">Medical Home</a></li>
                <li class="breadcrumb-item"><a href="/medical/neurological">Neurological</a></li>
                <li class="breadcrumb-item active" aria-current="page">Consideration of Nabiximols (Sativex®) Trial</li>
            </ol>
        </nav>
        <header class="mb-3">
            <h1>Consideration of Nabiximols (Sativex®) Trial for Central Neuropathic Pain</h1>
        </header>
        <section class="card-like meta mb-3">
            <p>
                <strong>Subject:</strong> Consideration of Nabiximols (Sativex&reg;) Trial for Central Neuropathic Pain<br>
                <strong>Date:</strong> [Draft]]
            </p>
            <p>
                This correspondence forms part of the ongoing multidisciplinary review of my neurological case led by <a href="https://www.circlehealthgroup.co.uk/consultants/omar-malik">Dr. Omar Malik at Mount Alvernia Hospital, Guildford</a></p>
        </section>
        <section class="card-like">
            <p><strong>Dear Dr Malik,</strong></p>
            <p>Following our recent discussions regarding the likely central origin of my neuropathic symptoms, and in light of my ongoing left-sided pain and sensory disturbance, I have been exploring evidence-based options for patients who do not tolerate, or gain limited benefit from, standard first-line agents.</p>
            <p>Given my poor tolerance of antidepressant and anticonvulsant medication, I would like to ask whether a monitored trial of <strong>Nabiximols (Sativex&reg;)</strong> might be clinically appropriate. The balanced THC–CBD formulation appears relevant to central post-stroke or brainstem-related neuropathic pain, acting on both nociceptive modulation and neuroinflammatory pathways.</p>
            <p>While its UK licence currently covers multiple-sclerosis-related spasticity, published evidence increasingly supports cautious off-label use for other central neuropathic pain syndromes. I would value your guidance on whether this could be considered within my current management plan, particularly as part of the ongoing multidisciplinary review.</p>
            <p>If you felt this justified, I would greatly appreciate your advice on:</p>
            <ul>
                <li>Whether a short monitored trial could be arranged under your supervision or via a pain specialist in your network</li>
                <li>Any formal criteria, consent, or funding routes required (including AXA support)</li>
                <li>Appropriate starting and titration parameters</li>
            </ul>
            <p>I fully appreciate the need for evidence-based prescribing and would approach this cautiously and collaboratively. My hope is to find an option that could improve quality of life and functional stability without recourse to higher-risk pharmacological agents.</p>
            <p>Thank you again for your care and ongoing consideration of my case.</p>
            <p><strong>Warm regards,<br>James Saint</strong></p>
        </section>
    <!-- Footer -->
<footer class="site-footer mt-4" role="contentinfo" aria-label="Site footer">
  <div class="footer-container text-center">
    <hr class="footer-rule" />
    <div class="footer-note mb-1">
      Private & Confidential · Intended for the named clinical team and the patient only.
    </div>
    <div class="footer-copy">
      © <span id="copy-year"></span> James Saint. All rights reserved.
    </div>
  </div>
</footer>
<!-- Year Autoupdate -->
<script>
  (function () {
    var y = new Date().getFullYear();
    var el = document.getElementById('copy-year');
    if (el) el.textContent = y;
  })();
</script>

    </main>
</body>

</html>